BELLICUM PHARMACEUTICALS, INC. Financials Bellicum Pharmaceuticals, Inc.
Equities
BPXA
US0794814048
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-2.31% | -53.99% |
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.185 | 1.12 | 7.143 | 0.5 | 6.2 | 1.5 |
| EBITDA 1 | -83.82 | -88.77 | -78.12 | -52.61 | -24.28 | -26.97 |
| EBIT 1 | -87.39 | -95.47 | -85.3 | -54.08 | -24.39 | -26.98 |
| Operating Margin | -47,236.22% | -8,523.75% | -1,194.18% | -10,816.6% | -393.35% | -1,798.73% |
| Earnings before Tax (EBT) 1 | -91.78 | -98.04 | -112.5 | -7.722 | -9.705 | -24.97 |
| Net income 1 | -91.78 | -98.04 | -112.5 | -7.722 | -9.705 | -24.97 |
| Net margin | -49,610.27% | -8,753.21% | -1,574.65% | -1,544.4% | -156.53% | -1,664.87% |
| EPS 2 | -28.94 | -24.37 | -24.01 | -1.341 | -0.8436 | -0.8101 |
| Free Cash Flow 1 | -53.23 | -38.4 | 8.89 | -70.84 | -27.87 | -16.19 |
| FCF margin | -28,775.61% | -3,428.81% | 124.45% | -14,168.75% | -449.45% | -1,079.54% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/13/18 | 3/12/19 | 3/12/20 | 3/31/21 | 3/24/22 | 3/31/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 63.8 | 57 | 53 | 34.3 | 46.2 | 21.8 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -53.2 | -38.4 | 8.89 | -70.8 | -27.9 | -16.2 |
| ROE (net income / shareholders' equity) | -101% | -128% | -353% | -143% | -33.5% | -79.9% |
| ROA (Net income/ Total Assets) | -40.8% | -46.4% | -44.8% | -43.1% | -34% | -46.2% |
| Assets 1 | 224.8 | 211.2 | 250.8 | 17.91 | 28.56 | 54.03 |
| Book Value Per Share 2 | 25.40 | 15.70 | -5.230 | -0.3000 | 2.890 | 0.2300 |
| Cash Flow per Share 2 | 11.70 | 10.00 | 18.20 | 4.270 | 5.480 | 2.530 |
| Capex 1 | 12.1 | 1.62 | 0.52 | 0.63 | 0.01 | 0.02 |
| Capex / Sales | 6,558.92% | 144.38% | 7.31% | 125% | 0.11% | 1.4% |
| Announcement Date | 3/13/18 | 3/12/19 | 3/12/20 | 3/31/21 | 3/24/22 | 3/31/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -53.99% | 822K | |
| +10.79% | 115B | |
| +11.65% | 106B | |
| -6.20% | 24.69B | |
| -2.33% | 21.97B | |
| -6.03% | 19.27B | |
| -13.41% | 17.56B | |
| -40.50% | 17.32B | |
| +6.64% | 14.03B | |
| +31.84% | 12.13B |
- Stock Market
- Equities
- BPXA Stock
- Financials Bellicum Pharmaceuticals, Inc.
